Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 30,600 shares, a drop of 28.2% from the March 31st total of 42,600 shares. Based on an average daily volume of 27,700 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.8% of the shares of the stock are sold short.

Assembly Biosciences Trading Down 5.3 %

ASMB traded down $0.71 during midday trading on Friday, hitting $12.65. The company’s stock had a trading volume of 29,550 shares, compared to its average volume of 17,185. The firm has a market cap of $69.36 million, a P/E ratio of -0.74 and a beta of 0.57. The firm has a 50-day moving average price of $13.07 and a two-hundred day moving average price of $11.07. Assembly Biosciences has a 52-week low of $7.69 and a 52-week high of $20.04.

Analyst Ratings Changes

A number of analysts recently commented on the company. StockNews.com upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st.

Institutional Trading of Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC bought a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences as of its most recent filing with the SEC. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.